Sharps Technology, Inc. (NASDAQ: STSS) saw its shares climb by 9.58% to $5.49 in recent trading following the announcement of its second shipment execution under a previously disclosed $50 million SoloGard syringe sales agreement. The development signifies a major step in STSS’ transition toward full-scale commercial operations and revenue generation.
Strategic Manufacturing Enhancements Underway
As part of a multi-year supply agreement with a well-known intravenous (IV) flushing solution supplier in the United States, Sharps Technology announced that it has started shipping the second shipment of its SoloGard safety syringes. STSS has finished installing new injection molding and automation systems, which are substantial enhancements that should greatly improve manufacturing capabilities and support predicted output increases in the second half of 2025.
Sharps Technology has decided to optimize manufacturing in stages. This entails using cutting-edge injection molding technologies, enhancing cleanroom procedures, and satisfying client demands for reliable, superior results. Installing cutting-edge equipment also results in a tenfold increase in energy efficiency, which lowers operating costs and supports environmental objectives.
Cleanroom and Control System Upgrades
Sharps Technology is also upgrading control systems and improving cleanroom conditions as part of its facility renovation initiatives. By using auxiliary technologies to increase throughput and optimize molding and assembly processes, these enhancements aim to maintain strict product quality standards and regulatory compliance.
Changing to Operations Driven by Revenue
Sharps Technology is currently fulfilling a $400,000 purchase order announced on June 4, 2025, which falls under a broader five-year agreement to supply up to 500 million SoloGard syringes. Among the goods are 10mL smart safety syringes that have been authorized by the FDA and WHO. They have low-waste designs, luer lock compatibility, and re-use prevention features.
In addition to reaching a significant milestone under the $50 million contract, Sharps Technology (STSS) establishes itself as a vital, innovative manufacturing partner to the healthcare sector by completing this second shipment. The company’s long-term objectives are efficiency, scalability, and recurring revenue streams.
